Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Circulating histones as clinical biomarkers in critically ill conditions

  • García-Giménez, José Luis|||0000-0001-7547-7872
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Durá, Raquel
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Bajaña, Iván
  • Bolado López de Andujar, David
  • Cánovas-Cervera, Irene|||0000-0001-9364-235X
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Chiscano-Camón, Luis|||0000-0003-0037-0610
  • Climent Martinez, Elena
  • García Fernández, Georgia
  • Gomà, Gemma|||0000-0002-1890-4855
  • Monforte, Verónica
  • Quevedo, Beatriz
  • Ruiz-Sanmartin, Adolf
  • Sierra Rivera, Antonio
  • Carbonell, Nieves|||0000-0002-9149-0310
Extracellular histones, primarily nuclear proteins involved in chromatin organization, have emerged as key mediators in pathological processes in critically ill patients. When released into circulation due to cell death mechanisms such as NETosis, histones act as damage-associated molecular patterns (DAMPs), contributing to excessive inflammation, endothelial dysfunction, immune response dysregulation, coagulation activation, cell death, and multi-organ damage. Increasing evidence supports their role in the pathophysiology of sepsis, acute lung injury, cardiac injury, pancreatitis, and other life-threatening conditions. Given their strong association with disease severity and prognosis, circulating histones have gained attention as potential clinical biomarkers for early diagnosis, prognosis, and therapeutic monitoring in critically ill patients. This review discusses the biological roles of extracellular histones, their potential as biomarkers, different approaches to measure them, and emerging therapeutic strategies aimed at neutralizing or removing circulating histones to improve patient outcomes in severe medical conditions. {'boxed-text': {'@position': 'anchor', '@content-type': 'box', '@id': 'feb270093-blkfxd-0001', '@orientation': 'portrait', 'caption': {'title': 'Impact statement'}, 'p': 'This review highlights extracellular histones as key mediators and biomarkers in sepsis, proposing their use in diagnosis, prognosis, and treatment monitoring. Integrating quantitative proteomics for the detection of circulating histones may enhance patient stratification and guide therapeutic strategies, advancing personalized medicine in critical care.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Emerging biomodels to understand the pathophysiology of sepsis and evaluate new therapeutic strategies targeting extracellular histones

  • Garcia-Gimenez, Jose Luis
  • Cervera, Marta Seco
  • Canovas-Cervera, Irene
  • Agundez, Ana Belen
  • Dolz-Andres, Enric
  • Mondaray-Munoz, Gonzalo
  • Calpe-Fortea, Rosa
  • Nacher-Sendra, Elena
  • Osca-Verdegal, Rebeca
  • Beltran-Garcia, Jesus
  • Sierra-Rivera, Antonio
  • Peiro-Chova, Lorena
  • Ibañez-Cabellos, J.S.
  • Aparicio-Collado, José Luís|||0000-0003-0874-9131
  • Gallego-Ferrer, Gloria|||0000-0002-2428-0903
[EN] Background: Extracellular histones (extH) have emerged as key damage-associated molecular patterns (DAMPs) driving multi-organ failure in sepsis. Despite their correlation with disease severity, organ-specific mechanisms of extH toxicity and targeted therapeutic strategies remain underexplored. Main body: This review dissects extH-mediated pathophysiology across vital organs including heart, lungs, kidneys, liver, and brain, through convergent pathways including TLR activation, NLRP3 inflammasome signaling, NETosis, oxidative stress, calcium influx, pyroptosis, and microvascular thrombosis. Conventional 2D cell cultures fail to recapitulate tissue architecture, multicellular interactions, and hemodynamic forces, while rodent models exhibit poor clinical translatability due to specific immune responses and physiology. Moreover, conventional 2D models and animal models do not usually cover the heterogenicity we can find in sepsis. In contrast, advanced human-relevant 3D biomodels offer transformative advantages: organoids faithfully recreate organ-specific cellular heterogeneity and developmental gradients; 3D-bioprinted biomodels provide precise spatial control of immune-endothelial-stromal interactions within biomimetic matrices; organ-on-chip platforms integrate physiological shear stress, dynamic flow, oxygen gradients, and real-time inter-organ communication, enabling study of extH-driven neutrophil adhesion, platelet aggregation, barrier dysfunction, and cytokine storms under clinically relevant conditions. Conclusion: Next-generation 3D biomodels overcome traditional translational barriers, facilitating the comprehension of the pathophysiological mechanisms occurring in tissues during sepsis. Moreover, these advanced biomodels enable high-throughput screening of extH-neutralizing agents (e.g., heparinoids, anti-histone antibodies) and hemoperfusion technologies, thereby advancing precision intensive care medicine. By bridging mechanistic insights to clinical strategies that mitigate inflammation, endothelial dysfunction, thrombosis and long-term sequelae, these platforms promise transformative advances in sepsis management and intensive care outcomes., We would like to thank all the funding bodies supporting our research projects, including the EIC Accelerator programme, supported by CDTI - NextGenerationEU (Ministerio de Ciencia, Innovacion y Universidades) , as well as the projects CPP2021/008643 and DTS24/00094 funded by the Spanish Ministry of Science and Innovation, projects PI22-00481 and PI25-00664 funded under the Accion Estrategica en Salud programme of the Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation) and the CIAICO/2023/168, CIAPOT/2024/19 and CIPROM/2022/43 PROMETEO project from Generalitat Valenciana. I.Canovas-Cervera thanks the Ministry of Science, Innovation, and Universities for FPU grant (FPU23/02919) J. Aparici-Collado would like to thank Agencia Espanola de Investigacion for a grant Torres Quevedo (PTQ2024-013788) .
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease

  • Priego-Parra, Bryan Adrián
  • Gallego-Durán, Rocío
  • Román-Calleja, Berenice M.
  • Velarde-Ruiz Velasco, José Antonio
  • Romero-Gómez, Manuel
  • Gracia-Sancho, Jordi
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Srr2-dependent SOX2 levels govern the chromatin and transcriptional landscape of adult neural stem cell fate decisions in mouse

  • Cruces-Salguero, Sara
  • Jordán-Pla, Antonio
  • Domingo-Muelas, Ana
  • Morante-Redolat, Jose Manuel
  • Rizzoti, Karine
  • Matheu, Ander
  • Fariñas, Isabel
  • Lovell-Badge, Robin
  • Moncho-Amor, Veronica
21 páginas, 4 figuras, Background: Stem cell maintenance and lineage commitment in the nervous system require precise regulation of transcription factors, with SOX2 serving as a pivotal regulator. SOX2 expression is controlled by multiple enhancers, including the Sox2 regulatory region 2 (Srr2). However, the specific role of Srr2 in adult neurogenesis and chromatin regulation during neural lineage commitment remains incompletely understood. Results: To dissect the function of Srr2, we generate a CRISPR-Cas9 mouse model harboring a targeted deletion of this enhancer. Srr2 deletion reduce SOX2 levels in proliferating, but not differentiating, neurosphere cultures, while impairing both neuronal and oligodendroglial differentiation. Paired bulk RNA-seq and ATAC-seq during proliferation and early differentiation reveal that loss of Srr2 induces widespread chromatin compaction during proliferation, which partially converges toward wild-type states upon early differentiation. Multi-omic integration identifies a subset of neurogenic genes exhibiting persistent promoter closure and impaired transcriptional induction in proliferating mutant cells, despite being normally translated during neural differentiation. In vivo, subependymal zone cells of Srr2del/del mice exhibit lower SOX2 and FOXG1 expression, fewer ASCL1/OLIG2 progenitors, and reduced neuronal and oligodendroglial marker expression. Conclusions: These findings establish Srr2 as a critical enhancer of Sox2 required to maintain a chromatin environment permissive for neural differentiation during stem cell proliferation. Our study underscores the essential role of non-coding regulatory elements in coordinating chromatin accessibility, transcriptional programs, and stem cell fate decisions during adult neurogenesis., Open Access funding provided by The Francis Crick Institute. This work was supported by Instituto de Salud Carlos III (ISCIII) through the project (PI19/01355, PI22/01905, FORT23-00026, DTS24/00153 and PI24/01542) and co-funded by the European Union, and the Health Department of the Basque Country (2022111069, 023333041 and 2024333025). Work at the I.F’s laboratory was supported by grants PID2023-152962NB-I00, CB06/05/0086 (CIBERNED) from Ministerio de Ciencia e Innovación, Prometeo CIPROM/2024/57 from Generalitat Valenciana, and ERC Advanced Grant 101098241 from the European Commission. S.C-S received a predoctoral fellowship from the Ministry of Science, Innovation and Universities (FPU23/01973) and the Spanish Association against Cancer (AECC—PRDGU246336CRUC). V.M-A received a Miguel Servet contract from the Instituto Salud Carlos III (CP23/00111). A.D-M was a recipient of a FPU PhD contract from Ministerio de Educación, Cultura y Deporte (MECD) and her stay at R.L-B’s laboratory was supported by a MECD’s grant included in the FPU program., Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Generation and validation of a novel multitarget small molecule in glioblastoma

  • Artetxe Zurutuza, Aizpea
  • Matheu, Ander
  • Iturrioz Rodríguez, Nerea
  • Elizazu, Joseba
  • Toledano Pinedo, Mireia
  • Porro Pérez, Alicia
  • Goni, Irati de
  • Elua Pinin, Alejandro
  • Schaker-Hubner, Linda
  • Azkargorta, Miquel
  • Elortza, Félix
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Marco Contelles, José Luis
The development of multitarget small molecules (MSMs) has emerged as a powerful strategy for the treatment of multifactorial diseases such as cancer. Glioblastoma is the most prevalent and malignant primary brain tumor in adults, which is characterized by poor prognosis and a high heterogeneity. Current standards of treatment present limited effectiveness, as patients develop therapy resistance and recur. In this work, we synthesized and characterized a novel multi-target molecule (named DDI199 or contilistat), which is a polyfunctionalized indole derivative developed by juxtaposing selected pharmacophoric moieties of the parent compounds Contilisant and Vorinostat (SAHA) to act as multifunctional ligands that inhibit histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors. DDI199 exerts high cytotoxic activity in conventional glioblastoma cell lines and patient-derived glioma stem cells in vitro. Importantly, it significantly reduces tumor growth in vivo, both alone and in combination with temozolomide (TMZ). The comparison with SAHA showed higher target specificity and antitumor activity of the new molecule. Transcriptomic and proteomic analyses of patient-derived glioma stem cells revealed a deregulation in cell cycle, DNA remodeling and neurotransmission activity by the treatment with DDI199. In conclusion, our data reveal the efficacy of a novel MSM in glioblastoma pre-clinical setting., Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades